{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dyslipidemias&page=3",
    "query": {
      "condition": "Dyslipidemias",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1119,
    "total_pages": 112,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dyslipidemias&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dyslipidemias&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T14:17:08.783Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00304993",
      "title": "Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metabolic Syndrome X",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "niacin",
          "type": "DRUG"
        },
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foundation Research, Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2001-01",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2006-03-21",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304993"
    },
    {
      "nct_id": "NCT02113163",
      "title": "PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Metformin Eicosapentaenoate",
          "type": "DRUG"
        },
        {
          "name": "Metformin HCl and Vascepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thetis Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-03",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113163"
    },
    {
      "nct_id": "NCT05700916",
      "title": "Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Dyslipidemias",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Milk Polar Lipid-Rich Dairy Powder",
          "type": "DRUG"
        },
        {
          "name": "Dairy Powder",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Connecticut",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 130,
      "start_date": "2023-10-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Storrs, Connecticut",
      "locations": [
        {
          "city": "Storrs",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05700916"
    },
    {
      "nct_id": "NCT01448304",
      "title": "Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "alirocumab SAR236553 (REGN727)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-06",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-06-28",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01448304"
    },
    {
      "nct_id": "NCT00326326",
      "title": "Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "CP-778,875",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 84,
      "start_date": "2006-07",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2009-05-07",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 31,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Greenbrae, California + 26 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326326"
    },
    {
      "nct_id": "NCT03501433",
      "title": "Effects of Nicotinamide Riboside on Metabolism and Vascular Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aging",
        "Lipemia"
      ],
      "interventions": [
        {
          "name": "Nicotinamide riboside chloride (Niagen)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Iowa State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2018-02-01",
      "completion_date": "2019-12-01",
      "has_results": false,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Ames, Iowa",
      "locations": [
        {
          "city": "Ames",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03501433"
    },
    {
      "nct_id": "NCT02345421",
      "title": "A Study to Identify and Characterize LAL-D Patients in High-risk Populations",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lysosomal Acid Lipase Deficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 640,
      "start_date": "2014-12",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-05-24",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345421"
    },
    {
      "nct_id": "NCT06647238",
      "title": "Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperlipidemia",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Pharmacist Intervention in lipid therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-11-05",
      "completion_date": "2025-05-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Concord, North Carolina",
      "locations": [
        {
          "city": "Concord",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06647238"
    },
    {
      "nct_id": "NCT00222833",
      "title": "The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overweight",
        "Hyperlipidemia",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-10",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222833"
    },
    {
      "nct_id": "NCT00443755",
      "title": "Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Insulin Resistance",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2005-08",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2013-10-31",
      "last_synced_at": "2026-10-19T14:17:08.783Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00443755"
    }
  ]
}